MVM Life Science Partners
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, China, France, Italy, Denmark, Switzerland, Spain, South Korea, Ireland, Austria, Netherlands, Sweden, Belgium, Norway, Finland
Industries Focus
- Healthcare Services
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Vaccines
- Healthcare IT
- Life Science Tools
- Gene Therapy
- Contract Manufacturing
- Consumer Healthcare
- Drug Delivery
- Contract Research
- Veterinary Medicine
Investment Size:
20,000,000 to 100,000,000 USD
Investor Details Founded: 1997
MVM Life Science Partners is a venture capital firm specializing in early-stage investments within the life sciences sector. Founded in 1997, the firm operates globally with offices in London and Boston, focusing on innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. MVM has raised multiple funds totaling over $700 million, supporting businesses across all stages of development, from early-stage private deals to publicly listed companies.
The firm's investment strategy combines deep sector expertise with strategic support to help portfolio companies achieve their full potential. MVM typically invests between $20 million and $100 million in each portfolio company over the holding period, with a focus on companies that address significant unmet needs in large addressable markets. The firm seeks out businesses with differentiated technologies and durable protection against competition, whether through intellectual property, barriers to market entry, statutory exclusivity, or unique branding.
MVM has a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide. The firm's portfolio includes notable companies such as Domantis, Heptares, Preglem, Momenta, Vascular Pathways, Beacon Endoscopic, Cara Therapeutics, Aegerion, and HBI. MVM's approach emphasizes collaboration with best-in-class management teams to bring innovative products to market, drive growth, make strategic acquisitions, and establish new standards of care in medicine.
Requirements
- High growth potential
- Differentiated technology
- Address significant unmet needs
- Large addressable markets
- Durable protection against competition
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Domantis
- Heptares
- Preglem
- Momenta
- Vascular Pathways
- Beacon Endoscopic
- Cara Therapeutics
- Aegerion
- HBI
Mentioned In
-
$24.95
-
$49.95
-
$19.95
-
$39.95
-
$19.95
-
$24.95
-
$99.00
-
$245.00
Claim this Investor
Are you an official representative of MVM Life Science Partners?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim